ProCE Banner Activity

KEYNOTE-006: Long-term Outcomes After Pembrolizumab for Advanced Melanoma

Slideset Download
Conference Coverage
A nearly 3-year follow-up confirmed superiority of pembrolizumab over ipilimumab in patients with advanced melanoma.

Released: June 05, 2017

Expiration: June 04, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology